Tom 10, Nr 3 (2019)
Artykuł przeglądowy
Opublikowany online: 2019-12-20
Pobierz cytowanie

Perspektywy rozwoju strategii terapeutycznych opartych na TRAIL i jego analogach w hematoonkologii

Karolina Piechna, Przemysław Juszczyński
DOI: 10.5603/Hem.2019.0028
·
Hematologia 2019;10(3):148-160.

dostęp płatny

Tom 10, Nr 3 (2019)
PRACE POGLĄDOWE
Opublikowany online: 2019-12-20

Streszczenie

TRAIL (TNF-related apoptosis-inducing ligand), białko należące do nadrodziny czynnika martwicy nowotworów, wywołuje apoptozę w komórkach nowotworowych, zachowując stosunkowo niską toksyczność wobec komórek niestransformowanych. Strategie terapeutyczne oparte na wykorzystaniu TRAIL lub jego analogów wykazują zwykle wysoką aktywność w modelach in vitro i przedklinicznych modelach in vivo. W badaniach klinicznych TRAIL i jego analogi charakteryzowały się niską toksycznością i z reguły były dobrze tolerowane, ale cechowała je niską skuteczność. Głównym ograniczeniem wykorzystania TRAIL w terapii jest pierwotna lub wtórna oporność komórek na indukowaną przez TRAIL apoptozę, wywoływana przez różne mechanizmy. Ponieważ część mechanizmów oporności może być modulowana farmakologicznie, to stanowią one potencjalny cel terapii łączonych uwrażliwiających na apoptozę zależną od receptorów śmierci. W pracy przedstawiono przegląd badań przedklinicznych i klinicznych, w których wykorzystywano terapie oparte na TRAIL lub jego analogach oraz perspektywy rozwoju takich strategii opartych na farmakologicznej modulacji mechanizmów oporności.

Streszczenie

TRAIL (TNF-related apoptosis-inducing ligand), białko należące do nadrodziny czynnika martwicy nowotworów, wywołuje apoptozę w komórkach nowotworowych, zachowując stosunkowo niską toksyczność wobec komórek niestransformowanych. Strategie terapeutyczne oparte na wykorzystaniu TRAIL lub jego analogów wykazują zwykle wysoką aktywność w modelach in vitro i przedklinicznych modelach in vivo. W badaniach klinicznych TRAIL i jego analogi charakteryzowały się niską toksycznością i z reguły były dobrze tolerowane, ale cechowała je niską skuteczność. Głównym ograniczeniem wykorzystania TRAIL w terapii jest pierwotna lub wtórna oporność komórek na indukowaną przez TRAIL apoptozę, wywoływana przez różne mechanizmy. Ponieważ część mechanizmów oporności może być modulowana farmakologicznie, to stanowią one potencjalny cel terapii łączonych uwrażliwiających na apoptozę zależną od receptorów śmierci. W pracy przedstawiono przegląd badań przedklinicznych i klinicznych, w których wykorzystywano terapie oparte na TRAIL lub jego analogach oraz perspektywy rozwoju takich strategii opartych na farmakologicznej modulacji mechanizmów oporności.

Pobierz cytowanie

Słowa kluczowe

TRAIL, receptory śmierci, DR4, DR5, mechanizmy oporności, apoptoza

Informacje o artykule
Tytuł

Perspektywy rozwoju strategii terapeutycznych opartych na TRAIL i jego analogach w hematoonkologii

Czasopismo

Hematologia

Numer

Tom 10, Nr 3 (2019)

Typ artykułu

Artykuł przeglądowy

Strony

148-160

Data publikacji on-line

2019-12-20

DOI

10.5603/Hem.2019.0028

Rekord bibliograficzny

Hematologia 2019;10(3):148-160.

Słowa kluczowe

TRAIL
receptory śmierci
DR4
DR5
mechanizmy oporności
apoptoza

Autorzy

Karolina Piechna
Przemysław Juszczyński

Referencje (108)
  1. Wiley SR, Schooley K, Smolak P, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 1995; 3(6): 673–682.
  2. Pitti RM, Marsters SA, Ruppert S, et al. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem. 1996; 271(22): 12687–12690.
  3. Walczak H, Miller RE, Ariail K, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med. 1999; 5(2): 157–163.
  4. Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest. 1999; 104(2): 155–162.
  5. Kischkel FC, Hellbardt S, Behrmann I, et al. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J. 1995; 14(22): 5579–5588.
  6. Stennicke HR, Jürgensmeier JM, Shin H, et al. Pro-caspase-3 is a major physiologic target of caspase-8. J Biol Chem. 1998; 273(42): 27084–27090.
  7. Jost PJ, Grabow S, Gray D, et al. XIAP discriminates between type I and type II FAS-induced apoptosis. Nature. 2009; 460(7258): 1035–1039.
  8. Lindsten T, Ross A, King A, et al. The combined functions of proapoptotic Bcl-2 family members Bak and Bax are essential for normal development of multiple tissues. Molecular Cell. 2000; 6(6): 1389–1399.
  9. Arnoult D. Mitochondrial release of AIF and EndoG requires caspase activation downstream of Bax/Bak-mediated permeabilization. EMBO J. 2003; 22(17): 4385–4399.
  10. Abdulghani J, El-Deiry WS. TRAIL receptor signaling and therapeutics. Expert Opin Ther Targets. 2010; 14(10): 1091–1108.
  11. Carlo-Stella C, Lavazza C, Locatelli A, et al. Targeting TRAIL agonistic receptors for cancer therapy. Clin Cancer Res. 2007; 13(8): 2313–2317.
  12. Herbst RS, Eckhardt SG, Kurzrock R, et al. Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol. 2010; 28(17): 2839–2846.
  13. Hotte SJ, Hirte HW, Chen EX, et al. A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies. Clin Cancer Res. 2008; 14(11): 3450–3455.
  14. Younes A, Vose JM, Zelenetz AD, et al. A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma. Br J Cancer. 2010; 103(12): 1783–1787.
  15. Rosevear HM, Lightfoot AJ, Griffith TS. Conatumumab, a fully human mAb against death receptor 5 for the treatment of cancer. Curr Opin Investig Drugs. 2010; 11(6): 688–698.
  16. Forero-Torres A, Shah J, Wood T, et al. Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5). Cancer Biother Radiopharm. 2010; 25(1): 13–19.
  17. Camidge DR, Herbst RS, Gordon MS, et al. A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies. Clin Cancer Res. 2010; 16(4): 1256–1263.
  18. Plummer R, Attard G, Pacey S, et al. Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers. Clin Cancer Res. 2007; 13(20): 6187–6194.
  19. Tahir SK, Smith ML, Solomon LR, et al. Abbv-621 is a novel and potent TRAIL receptor agonist fusion protein that induces apoptosis alone and in combination with navitoclax and venetoclax in hematological tumors. Blood. 2017; 130(Suppl 1).
  20. Green DR, Evan G. A matter of life and death. Cancer Cell. 2002; 1(1): 19–30.
  21. Wagner KW, King F, Nomoto K, et al. Activation and suppression of the TRAIL death-receptor pathway in chemotherapy sensitive and resistant follicular lymphoma cells. Cancer Biol Ther. 2003; 2(5): 534–540.
  22. Yu J, Zhang L. PUMA, a potent killer with or without p53. Oncogene. 2008; 27 Suppl 1: S71–S83.
  23. Hellwig CT, Rehm M. TRAIL signaling and synergy mechanisms used in TRAIL-based combination therapies. Mol Cancer Ther. 2012; 11(1): 3–13.
  24. Prokocimer M, Molchadsky A, Rotter V. Dysfunctional diversity of p53 proteins in adult acute myeloid leukemia: projections on diagnostic workup and therapy. Blood. 2017; 130(6): 699–712.
  25. Jiang H, Reinhardt HC, Bartkova J, et al. The combined status of ATM and p53 link tumor development with therapeutic response. Genes Dev. 2009; 23(16): 1895–1909.
  26. Weber AM, Ryan AJ. ATM and ATR as therapeutic targets in cancer. Pharmacol Ther. 2015; 149: 124–138.
  27. Wade M, Li YC, Wahl GM. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer. 2013; 13(2): 83–96.
  28. Baritaki S, Huerta-Yepez S, Sakai T, et al. Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: up-regulation of DR5 and inhibition of Yin Yang 1. Mol Cancer Ther. 2007; 6(4): 1387–1399.
  29. Ganten TM, Haas TL, Sykora J, et al. Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs. Cell Death Differ. 2004; 11(Suppl 1): S86–S96.
  30. Soria JC, Márk Z, Zatloukal P, et al. Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer. J Clin Oncol. 2011; 29(33): 4442–4451.
  31. Leong S, Cohen RB, Gustafson DL, et al. Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study. J Clin Oncol. 2009; 27(26): 4413–4421.
  32. Mom CH, Verweij J, Oldenhuis CN, et al. Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study. Clin Cancer Res. 2009; 15(17): 5584–5590.
  33. Reck M, Krzakowski M, Chmielowska E, et al. A randomized, double-blind, placebo-controlled phase 2 study of tigatuzumab (CS-1008) in combination with carboplatin/paclitaxel in patients with chemotherapy-naïve metastatic/unresectable non-small cell lung cancer. Lung Cancer. 2013; 82(3): 441–448.
  34. Kindler HL, Richards DA, Garbo LE, et al. A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer. Ann Oncol. 2012; 23(11): 2834–2842.
  35. Chinnaiyan AM, Prasad U, Shankar S, et al. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc Natl Acad Sci U S A. 2000; 97(4): 1754–1759.
  36. Maduro JH, de Vries EGE, Meersma GJ, et al. Targeting pro-apoptotic trail receptors sensitizes HeLa cervical cancer cells to irradiation-induced apoptosis. Int J Radiat Oncol Biol Phys. 2008; 72(2): 543–552.
  37. Norbury CJ, Zhivotovsky B. DNA damage-induced apoptosis. Oncogene. 2004; 23(16): 2797–2808.
  38. Vogler M, Dinsdale D, Dyer MJS, et al. Bcl-2 inhibitors: small molecules with a big impact on cancer therapy. Cell Death Differ. 2009; 16(3): 360–367.
  39. Mott JL, Bronk SF, Mesa RA, et al. BH3-only protein mimetic obatoclax sensitizes cholangiocarcinoma cells to Apo2L/TRAIL-induced apoptosis. Mol Cancer Ther. 2008; 7(8): 2339–2347.
  40. Huang S, Okumura K, Sinicrope FA. BH3 mimetic obatoclax enhances TRAIL-mediated apoptosis in human pancreatic cancer cells. Clin Cancer Res. 2009; 15(1): 150–159.
  41. Song JH, Kandasamy K, Kraft AS. ABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL-induced apoptosis. J Biol Chem. 2008; 283(36): 25003–25013.
  42. Kisim A, Atmaca H, Cakar B, et al. Pretreatment with AT-101 enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis of breast cancer cells by inducing death receptors 4 and 5 protein levels. J Cancer Res Clin Oncol. 2012; 138(7): 1155–1163.
  43. Wang G, Zhan Y, Wang H, et al. ABT-263 sensitizes TRAIL-resistant hepatocarcinoma cells by downregulating the Bcl-2 family of anti-apoptotic protein. Cancer Chemother Pharmacol. 2012; 69(3): 799–805.
  44. Yeow WC, Baras A, Chua A, et al. Gossypol, a phytochemical with BH3-mimetic property, sensitizes cultured thoracic cancer cells to Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand. J Thorac Cardiovasc Surg. 2006; 132(6): 1356–1362.
  45. Fresquet V, Rieger M, Carolis C, et al. Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma. Blood. 2014; 123(26): 4111–4119.
  46. Menke C, Bin L, Thorburn J, et al. Distinct TRAIL resistance mechanisms can be overcome by proteasome inhibition but not generally by synergizing agents. Cancer Res. 2011; 71(5): 1883–1892.
  47. Degli-Esposti MA, Dougall W, Smolak P, et al. The novel receptor TRAIL-R4 induces NF-κB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity. 1997; 7(6): 813–820.
  48. Cusack JC, Liu R, Houston M. Proteasome inhibition in cancer: development of PS-341. Cancer Res. 2001; 61(9): 3535–3540.
  49. Walter P, Ron D. The unfolded protein response: from stress pathway to homeostatic regulation. Science. 2011; 334(6059): 1081–1086.
  50. Koschny R, Ganten TM, Sykora J, et al. TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic window. Hepatology. 2007; 45(3): 649–658.
  51. Liu X, Yue P, Chen S, et al. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells. Cancer Res. 2007; 67(10): 4981–4988.
  52. Voortman J, Resende TP, Abou El Hassan MAI, et al. TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib. Mol Cancer Ther. 2007; 6(7): 2103–2112.
  53. Conticello C, Adamo L, Vicari L, et al. Antitumor activity of bortezomib alone and in combination with TRAIL in human acute myeloid leukemia. Acta Haematol. 2008; 120(1): 19–30.
  54. Jane EP, Premkumar DR, Pollack IF. Bortezomib sensitizes malignant human glioma cells to TRAIL, mediated by inhibition of the NF-{kappa}B signaling pathway. Mol Cancer Ther. 2011; 10(1): 198–208.
  55. Belch A, Sharma A, Spencer A, et al. A multicenter randomized phase II trial of mapatumumab, a TRAIL-R1 agonist monoclonal antibody, in combination with bortezomib in patients with relapsed/refractory multiple myeloma (MM). Blood. 2010; 116(21): 5031–5031.
  56. Younes A, Kirschbaum M, Sokol L, et al. Safety and tolerability of conatumumab in combination with bortezomib or vorinostat in patients with relapsed or refractory lymphoma. Blood. 2009; 114(22): 1708–1708.
  57. Finlay D, Teriete P, Vamos M, et al. Inducing death in tumor cells: roles of the inhibitor of apoptosis proteins. F1000Res. 2017; 6: 587.
  58. Vince JE, Wong WWL, Khan N, et al. IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell. 2007; 131(4): 682–693.
  59. Varfolomeev E, Blankenship JW, Wayson SM. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell. 2007; 131(4.): 669–681.
  60. Fulda S, Wick W, Weller M, et al. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med. 2002; 8(8): 808–815.
  61. Beug ST, Tang VA, LaCasse EC, et al. Smac mimetics and innate immune stimuli synergize to promote tumor death. Nat Biotechnol. 2014; 32(2): 182–190.
  62. Lu J, McEachern D, Sun H, et al. Therapeutic potential and molecular mechanism of a novel, potent, nonpeptide, Smac mimetic SM-164 in combination with TRAIL for cancer treatment. Mol Cancer Ther. 2011; 10(5): 902–914.
  63. Stadel D, Mohr A, Ref C, et al. TRAIL-induced apoptosis is preferentially mediated via TRAIL receptor 1 in pancreatic carcinoma cells and profoundly enhanced by XIAP inhibitors. Clin Cancer Res. 2010; 16(23): 5734–5749.
  64. Perimenis P, Galaris A, Voulgari A, et al. IAP antagonists birinapant and AT-406 efficiently synergise with either TRAIL, BRAF, or BCL-2 inhibitors to sensitise BRAFV600E colorectal tumour cells to apoptosis. BMC Cancer. 2016; 16: 624.
  65. Bae SI, Cheriyath V, Jacobs BS, et al. Reversal of methylation silencing of Apo2L/TRAIL receptor 1 (DR4) expression overcomes resistance of SK-MEL-3 and SK-MEL-28 melanoma cells to interferons (IFNs) or Apo2L/TRAIL. Oncogene. 2008; 27(4): 490–498.
  66. Hopkins-Donaldson S, Ziegler A, Kurtz S, et al. Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA methylation. Cell Death Differ. 2003; 10(3): 356–364.
  67. Siraj AK, Hussain AR, Al-Rasheed M, et al. Demethylation of TMS1 gene sensitizes thyroid cancer cells to TRAIL-induced apoptosis. J Clin Endocrinol Metab. 2011; 96(1): E215–E224.
  68. Gray SG, Ekström TJ. The human histone deacetylase family. Exp Cell Res. 2001; 262(2): 75–83.
  69. Ki HJ, Bae SC. Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. Am J Transl Res. 2011; 3(2): 166–179.
  70. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006; 5(9): 769–784.
  71. Fulda S. Modulation of TRAIL-induced apoptosis by HDAC inhibitors. Curr Cancer Drug Targets. 2008; 8(2): 132–140.
  72. Trivedi R, Mishra DP. Trailing TRAIL resistance: novel targets for TRAIL sensitization in cancer cells. Front Oncol. 2015; 5: 69.
  73. Guo F, Sigua C, Tao J, et al. Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells. Cancer Res. 2004; 64(7): 2580–2589.
  74. Venza I, Visalli M, Oteri R, et al. Class I-specific histone deacetylase inhibitor MS-275 overrides TRAIL-resistance in melanoma cells by downregulating c-FLIP. Int Immunopharmacol. 2014; 21(2): 439–446.
  75. Häcker S, Dittrich A, Mohr A, et al. Histone deacetylase inhibitors cooperate with IFN-gamma to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8. Oncogene. 2009; 28(35): 3097–3110.
  76. Fulda S. Histone deacetylase (HDAC) inhibitors and regulation of TRAIL-induced apoptosis. Exp Cell Res. 2012; 318(11): 1208–1212.
  77. Reddy RM, Yeow WS, Chua A, et al. Rapid and profound potentiation of Apo2L/TRAIL-mediated cytotoxicity and apoptosis in thoracic cancer cells by the histone deacetylase inhibitor Trichostatin A: the essential role of the mitochondria-mediated caspase activation cascade. Apoptosis. 2007; 12(1): 71–71.
  78. Rosato RR, Almenara JA, Dai Y, et al. Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells. Mol Cancer Ther. 2003; 2(12): 1273–1284.
  79. Ziauddin MF, Yeow WS, Maxhimer JB, et al. Valproic acid, an antiepileptic drug with histone deacetylase inhibitory activity, potentiates the cytotoxic effect of Apo2L/TRAIL on cultured thoracic cancer cells through mitochondria-dependent caspase activation. Neoplasia. 2006; 8(6): 446–457.
  80. Twomey JD, Kim SR, Zhao L, et al. Spatial dynamics of TRAIL death receptors in cancer cells. Drug Resist Updat. 2015; 19: 13–21.
  81. Yoshida T, Zhang Y, Rivera Rosado LA, et al. Repeated treatment with subtoxic doses of TRAIL induces resistance to apoptosis through its death receptors in MDA-MB-231 breast cancer cells. Mol Cancer Res. 2009; 7(11): 1835–1844.
  82. Zhang Y, Yoshida T, Zhang B. TRAIL induces endocytosis of its death receptors in MDA-MB-231 breast cancer cells. Cancer Biol Ther. 2009; 8(10): 917–922.
  83. Kohlhaas SL, Craxton A, Sun XM, et al. Receptor-mediated endocytosis is not required for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. J Biol Chem. 2007; 282(17): 12831–12841.
  84. Reis CR, Chen PH, Bendris N, et al. TRAIL-death receptor endocytosis and apoptosis are selectively regulated by dynamin-1 activation. Proc Natl Acad Sci U S A. 2017; 114(3): 504–509.
  85. Wang LH, Rothberg KG, Anderson RG. Mis-assembly of clathrin lattices on endosomes reveals a regulatory switch for coated pit formation. J Cell Biol. 1993; 123(5): 1107–1117.
  86. McGookey DJ, Fagerberg K, Anderson RG. Filipin-cholesterol complexes form in uncoated vesicle membrane derived from coated vesicles during receptor-mediated endocytosis of low density lipoprotein. J Cell Biol. 1983; 96(5): 1273–1278.
  87. Kilsdonk EP, Yancey PG, Stoudt GW, et al. Cellular cholesterol efflux mediated by cyclodextrins. J Biol Chem. 1995; 270(29): 17250–17256.
  88. Zhang Y, Zhang B. TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5. Mol Cancer Res. 2008; 6(12): 1861–1871.
  89. Macia E, Ehrlich M, Massol R, et al. Dynasore, a cell-permeable inhibitor of dynamin. Dev Cell. 2006; 10(6): 839–850.
  90. Hill TA, Gordon CP, McGeachie AB, et al. Inhibition of dynamin mediated endocytosis by the dynoles — synthesis and functional activity of a family of indoles. J Med Chem. 2009; 52(12): 3762–3773.
  91. von Kleist L, Stahlschmidt W, Bulut H, et al. Role of the clathrin terminal domain in regulating coated pit dynamics revealed by small molecule inhibition. Cell. 2011; 146(3): 471–484.
  92. Dutta D, Donaldson JG. Search for inhibitors of endocytosis: Intended specificity and unintended consequences. Cell Logist. 2012; 2(4): 203–208.
  93. Paul MK, Mukhopadhyay AK. Tyrosine kinase — role and significance in cancer. Int J Med Sci. 2004; 1(2): 101–115.
  94. Harper N, Hughes MA, Farrow SN, et al. Protein kinase C modulates tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by targeting the apical events of death receptor signaling. J Biol Chem. 2003; 278(45): 44338–44347.
  95. Cursi S, Rufini A, Stagni V, et al. Src kinase phosphorylates caspase-8 on Tyr380: a novel mechanism of apoptosis suppression. EMBO J. 2006; 25(9): 1895–1905.
  96. Söderström TS, Poukkula M, Holmström TH, et al. Mitogen-activated protein kinase/extracellular signal-regulated kinase signaling in activated T cells abrogates TRAIL-induced apoptosis upstream of the mitochondrial amplification loop and caspase-8. J Immunol. 2002; 169(6): 2851–2860.
  97. Desagher S, Osen-Sand A, Montessuit S, et al. Phosphorylation of bid by casein kinases I and II regulates its cleavage by caspase 8. Molecular Cell. 2001; 8(3): 601–611.
  98. Hellwig CT, Ludwig-Galezowska AH, Concannon CG, et al. Activity of protein kinase CK2 uncouples Bid cleavage from caspase-8 activation. J Cell Sci. 2010; 123(Pt 9): 1401–1406.
  99. Chen KF, Tai WT, Liu TH, et al. Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3. Clin Cancer Res. 2010; 16(21): 5189–5199.
  100. Chen KF, Chen HL, Shiau CW, et al. Sorafenib and its derivative SC-49 sensitize hepatocellular carcinoma cells to CS-1008, a humanized anti-TNFRSF10B (DR5) antibody. Br J Pharmacol. 2013; 168(3): 658–672.
  101. Rosato RR, Almenara JA, Coe S, et al. The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation. Cancer Res. 2007; 67(19): 9490–9500.
  102. Ciuleanu T, Bazin I, Lungulescu D, et al. A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma. Ann Oncol. 2016; 27(4): 680–687.
  103. Tazzari PL, Tabellini G, Ricci F, et al. Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor Perifosine in acute myelogenous leukemia cells. Cancer Res. 2008; 68(22): 9394–9403.
  104. Nesterov A, Lu X, Johnson M, et al. Elevated AKT activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis. J Biol Chem. 2001; 276(14): 10767–10774.
  105. Szegezdi E, Logue SE, Gorman AM, et al. Mediators of endoplasmic reticulum stress-induced apoptosis. EMBO Rep. 2006; 7(9): 880–885.
  106. Martín-Pérez R, Niwa M, López-Rivas A. ER stress sensitizes cells to TRAIL through down-regulation of FLIP and Mcl-1 and PERK-dependent up-regulation of TRAIL-R2. Apoptosis. 2012; 17(4): 349–363.
  107. Tiwary R, Yu W, Li J, et al. Role of endoplasmic reticulum stress in alpha-TEA mediated TRAIL/DR5 death receptor dependent apoptosis. PLoS One. 2010; 5(7): e11865.
  108. Letai AG. Diagnosing and exploiting cancer's addiction to blocks in apoptosis. Nat Rev Cancer. 2008; 8(2): 121–132.

Ważne: serwis https://journals.viamedica.pl/ wykorzystuje pliki cookies. Więcej >>

Używamy informacji zapisanych za pomocą plików cookies m.in. w celach statystycznych, dostosowania serwisu do potrzeb użytkownika (np. język interfejsu) i do obsługi logowania użytkowników. W ustawieniach przeglądarki internetowej można zmienić opcje dotyczące cookies. Korzystanie z serwisu bez zmiany ustawień dotyczących cookies oznacza, że będą one zapisane w pamięci komputera. Więcej informacji można znaleźć w naszej Polityce prywatności.

Czym są i do czego służą pliki cookie możesz dowiedzieć się na stronie wszystkoociasteczkach.pl.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl